Literature DB >> 19940803

VKORC1 pharmacogenomics summary.

Ryan P Owen1, Li Gong, Hersh Sagreiya, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19940803      PMCID： PMC3086043          DOI： 10.1097/FPC.0b013e32833433b6

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  28 in total

Review 1.  Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.

Authors:  H Takahashi; H Echizen
Journal:  Pharmacogenomics J       Date:  2003       Impact factor: 3.550

2.  Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.

Authors:  M-S Wen; Mtm Lee; J-J Chen; H-P Chuang; L-S Lu; C-H Chen; T-H Lee; C-T Kuo; F-M Sun; Y-J Chang; P-L Kuan; Y-F Chen; M-J Charng; C-Y Ray; J-Y Wu; Y-T Chen
Journal:  Clin Pharmacol Ther       Date:  2008-01-09       Impact factor: 6.875

Review 3.  Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.

Authors:  Elizabeth A Sconce; Farhad Kamali
Journal:  Eur J Haematol       Date:  2006-10-17       Impact factor: 2.997

4.  A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.

Authors:  R L D'Ambrosio; G D'Andrea; A Cafolla; F Faillace; M Margaglione
Journal:  J Thromb Haemost       Date:  2006-10-12       Impact factor: 5.824

Review 5.  Pharmacogenetics of warfarin: current status and future challenges.

Authors:  M Wadelius; M Pirmohamed
Journal:  Pharmacogenomics J       Date:  2006-09-19       Impact factor: 3.550

6.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

Review 7.  Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Authors:  Tong Yin; Toshiyuki Miyata
Journal:  Thromb Res       Date:  2006-12-11       Impact factor: 3.944

8.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Authors:  Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

Review 9.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

10.  Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Authors:  B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875
View more
  32 in total

1.  Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

Authors:  Tuukka A Helin; Lotta Joutsi-Korhonen; Heidi Asmundela; Mikko Niemi; Arto Orpana; Riitta Lassila
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

2.  Pharmacogenomics and bioinformatics: PharmGKB.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

3.  Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences.

Authors:  A Sivadas; M Z Salleh; L K Teh; V Scaria
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

4.  The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Authors:  Susan I Vear; Gregory D Ayers; Sara L Van Driest; Robert F Sidonio; Charles Michael Stein; Richard H Ho
Journal:  Br J Haematol       Date:  2014-03-06       Impact factor: 6.998

Review 5.  Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2020-05-04       Impact factor: 5.568

6.  Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.

Authors:  Nishank Jain; Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-25       Impact factor: 8.237

7.  Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy.

Authors:  Shuang Li; Shixuan Liu; Xiaoran Roger Liu; Mengru Mira Zhang; Weikai Li
Journal:  Blood Adv       Date:  2020-05-26

8.  Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.

Authors:  Saurabh Singh Rathore; Surendra Kumar Agarwal; Shantanu Pande; Sushil Kumar Singh; Tulika Mittal; Balraj Mittal
Journal:  Indian J Clin Biochem       Date:  2011-05-01

9.  Pharmacogenomic analysis of a genetically distinct Indigenous population.

Authors:  Arvind Jaya Shankar; Sudhir Jadhao; Wendy Hoy; Simon J Foote; Hardip R Patel; Vinod Scaria; Brendan J McMorran; Shivashankar H Nagaraj
Journal:  Pharmacogenomics J       Date:  2021-11-25       Impact factor: 3.245

10.  Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.

Authors:  Maryam H Alrashid; Ahmad Al-Serri; Salem H Alshemmari; Philip Koshi; Suzanne A Al-Bustan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.